Our competition / Research, page-12

i know Lollies is paid to downramp. but, the replies back to his/her dumb comments are sometimes good quality information.

torn. ive blocked that user so the only way i can see their post is if someone replies to it.

but lets not all get sidetracked here. this is still an undervalued business.
- company fundamentals have not changed.
- growing revenues & constant customer acquisition
- no long term debt
- positive news flow expected in the coming weeks of future contracts and/or potential revenue streams. specifically nutraceuticals. ling maw is all well and good but i think the demand is only limited to the Asian region and some niche markets whereas nutraceuticals have a global market scalability.
- break even inflexion point within reach in the next 2 qtrs or so. rerate coming.
- factory is finished ready for 24/7 production (if i was ceo i wouldnt spend all that capex without being 100% sure the factory will be in full swing in the future)
- as far as i can tell from the webinars and interviews amd the way they are being remunerated, we have a good honest management team with integrity and is on the side of the shareholders.
- the recent spp is helping us LT SHs cash up the business for future growth

as always DYOR and make sure you buy wonderful companies at a margin of safety price. this is one of those leave it in the bottom drawer stocks. just come back 5 years from now to count how many bags we get.